IN2013MN02443A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MN02443A IN2013MN02443A IN2443MUN2013A IN2013MN02443A IN 2013MN02443 A IN2013MN02443 A IN 2013MN02443A IN 2443MUN2013 A IN2443MUN2013 A IN 2443MUN2013A IN 2013MN02443 A IN2013MN02443 A IN 2013MN02443A
- Authority
- IN
- India
- Prior art keywords
- pyrroloquinolinyl
- pyrrole
- dione
- formulations
- administering
- Prior art date
Links
- SIZLWFSPEDTFOD-UHFFFAOYSA-N 2-(1H-pyrrol-2-yl)-1H-pyrrolo[2,3-h]quinoline Chemical compound N1C(=CC=C2C=CC=3C(=C12)C=CN3)C=3NC=CC3 SIZLWFSPEDTFOD-UHFFFAOYSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505175P | 2011-07-07 | 2011-07-07 | |
| PCT/US2012/045688 WO2013006761A2 (en) | 2011-07-07 | 2012-07-06 | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013MN02443A true IN2013MN02443A (instruction) | 2015-06-12 |
Family
ID=47437711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2443MUN2013 IN2013MN02443A (instruction) | 2011-07-07 | 2012-07-06 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9180099B2 (instruction) |
| EP (1) | EP2729145A4 (instruction) |
| JP (1) | JP6073310B2 (instruction) |
| KR (1) | KR20140146036A (instruction) |
| CN (1) | CN103930110A (instruction) |
| AU (1) | AU2012278831A1 (instruction) |
| BR (1) | BR112013033807A2 (instruction) |
| CA (1) | CA2839584A1 (instruction) |
| IN (1) | IN2013MN02443A (instruction) |
| MX (1) | MX2014000253A (instruction) |
| PH (2) | PH12014500055A1 (instruction) |
| TW (1) | TW201315470A (instruction) |
| WO (1) | WO2013006761A2 (instruction) |
| ZA (1) | ZA201400108B (instruction) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2354267T3 (es) * | 2005-02-09 | 2011-03-11 | Arqule, Inc. | Derivados de maleimida, composiciones farmacéuticas y métodos para el tratamiento del cáncer. |
| KR20150003768A (ko) | 2012-04-23 | 2015-01-09 | 아르퀼 인코포레이티드 | 고순도 피롤로퀴놀리닐-피롤-2,5-디온 및 피롤로퀴놀리닐-피롤리딘-2,5-디온 및 이의 제조 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| SI1294358T1 (en) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Wet milling process |
| EP1551457A1 (en) | 2002-07-16 | 2005-07-13 | Elan Pharma International Limited | Liquid dosage compositions of stable nanoparticulate active agents |
| UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
| WO2006087919A1 (ja) * | 2005-01-28 | 2006-08-24 | Takeda Pharmaceutical Company Limited | 難水溶性物質含有微細化組成物 |
| ES2354267T3 (es) * | 2005-02-09 | 2011-03-11 | Arqule, Inc. | Derivados de maleimida, composiciones farmacéuticas y métodos para el tratamiento del cáncer. |
| DK1897558T3 (da) | 2005-06-09 | 2013-12-09 | Norgine Bv | Fast præparat af 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-on |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| EP2001498A4 (en) * | 2006-03-20 | 2013-01-23 | Vertex Pharma | PHARMACEUTICAL COMPOSITIONS |
| TWI405590B (zh) | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
| CN101474175B (zh) * | 2009-01-20 | 2014-07-02 | 重庆医药工业研究院有限责任公司 | 一种高生物利用度非布司他口服固体制剂及其制备方法 |
| MX2011008584A (es) * | 2009-02-12 | 2012-01-27 | Kyowa Hakko Kirin Co Ltd | Composiciones combinacionales y metodos para el tratamiento del cancer. |
| JP2013515737A (ja) * | 2009-12-23 | 2013-05-09 | アークル インコーポレイテッド | 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法 |
-
2012
- 2012-07-06 BR BR112013033807A patent/BR112013033807A2/pt not_active IP Right Cessation
- 2012-07-06 CA CA2839584A patent/CA2839584A1/en not_active Abandoned
- 2012-07-06 KR KR1020147001774A patent/KR20140146036A/ko not_active Withdrawn
- 2012-07-06 CN CN201280043415.6A patent/CN103930110A/zh active Pending
- 2012-07-06 JP JP2014519316A patent/JP6073310B2/ja active Active
- 2012-07-06 MX MX2014000253A patent/MX2014000253A/es unknown
- 2012-07-06 TW TW101124460A patent/TW201315470A/zh unknown
- 2012-07-06 PH PH1/2014/500055A patent/PH12014500055A1/en unknown
- 2012-07-06 EP EP12807740.1A patent/EP2729145A4/en not_active Withdrawn
- 2012-07-06 AU AU2012278831A patent/AU2012278831A1/en not_active Abandoned
- 2012-07-06 US US13/543,007 patent/US9180099B2/en active Active
- 2012-07-06 IN IN2443MUN2013 patent/IN2013MN02443A/en unknown
- 2012-07-06 WO PCT/US2012/045688 patent/WO2013006761A2/en active Application Filing
-
2014
- 2014-01-07 ZA ZA2014/00108A patent/ZA201400108B/en unknown
-
2015
- 2015-09-07 PH PH12015501980A patent/PH12015501980A1/en unknown
- 2015-10-08 US US14/878,203 patent/US20160022667A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160022667A1 (en) | 2016-01-28 |
| ZA201400108B (en) | 2016-03-30 |
| PH12014500055A1 (en) | 2016-02-08 |
| MX2014000253A (es) | 2014-10-17 |
| US20130011481A1 (en) | 2013-01-10 |
| JP2014518284A (ja) | 2014-07-28 |
| CN103930110A (zh) | 2014-07-16 |
| PH12015501980A1 (en) | 2017-10-18 |
| EP2729145A2 (en) | 2014-05-14 |
| JP6073310B2 (ja) | 2017-02-01 |
| EP2729145A4 (en) | 2014-12-10 |
| US9180099B2 (en) | 2015-11-10 |
| TW201315470A (zh) | 2013-04-16 |
| WO2013006761A3 (en) | 2013-04-18 |
| AU2012278831A1 (en) | 2014-01-16 |
| WO2013006761A2 (en) | 2013-01-10 |
| KR20140146036A (ko) | 2014-12-24 |
| BR112013033807A2 (pt) | 2017-02-14 |
| CA2839584A1 (en) | 2013-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501410A1 (en) | Therapeutically active compounds and their method of use | |
| PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| MX350432B (es) | Compuestos terapeuticamente activos y sus metodos de empleo. | |
| PH12014501561A1 (en) | Therapeutically active compounds and their methods of use | |
| MX2013011922A (es) | Compuestos de benceno substituido. | |
| MX342951B (es) | Composiciones terapeuticamente activas y su metodo de uso. | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| MY166171A (en) | Aryl- or heteroaryl-substituted benzene compounds | |
| PH12015500825B1 (en) | Substituted benzene compounds | |
| MY157124A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| PH12012501337A1 (en) | Substituted pyrrolo-aminopyrimidine compounds | |
| PH12013500955A1 (en) | Spiro-oxindole mdm2 antagonists | |
| CR20200479A (es) | COMPUESTOS TERAPÉUTICAMENTE ACTIVOS Y SUS MÉTODOS DE USO (Divisional 2016-0069) | |
| MX2009013815A (es) | Compuestos de quinazolinona y metodos de uso para los mismos. | |
| PH12012501556A1 (en) | Substituted naphthalenyl-pyrimidine compounds | |
| IN2013MN02443A (instruction) | ||
| MX359171B (es) | Tratamiento para diabetes tipo i y tipo ii. | |
| MX2012007471A (es) | Compuestos substituidos de pirrolo-aminopirimidina. |